Anti-acetylated-tau immunotherapy is neuroprotective in tauopathy and brain injury

Celeste Parra Bravo,Karen Krukowski,Sarah Barker,Chao Wang,Yaqiao Li,Li Fan,Edwin Vázquez-Rosa,Min-Kyoo Shin,Man Ying Wong,Louise D. McCullough,Ryan S. Kitagawa,H. Alex Choi,Angela Cacace,Subhash C. Sinha,Andrew A. Pieper,Susanna Rosi,Xu Chen,Li Gan

DOI: https://doi.org/10.1186/s13024-024-00733-9

2024-06-27

Molecular Neurodegeneration

Abstract:Tau is aberrantly acetylated in various neurodegenerative conditions, including Alzheimer's disease, frontotemporal lobar degeneration (FTLD), and traumatic brain injury (TBI). Previously, we reported that reducing acetylated tau by pharmacologically inhibiting p300-mediated tau acetylation at lysine 174 reduces tau pathology and improves cognitive function in animal models.

neurosciences